Results 51 to 60 of about 5,123 (202)

Trends and Patterns of Adverse Drug Reaction Reporting in Sierra Leone: A Retrospective Analysis of VigiFlow Data (2008–2022)

open access: yesPharmacoepidemiology and Drug Safety, Volume 35, Issue 3, March 2026.
ABSTRACT Purpose Adverse drug reactions (ADRs) present significant obstacles for healthcare systems, impacting both patient safety and the effectiveness of treatments. Despite this, there is a scarcity of research on ADR reports in Sierra Leone, especially over long periods.
Isatu Jalloh   +4 more
wiley   +1 more source

PSY34 Economic Evaluation of Ferinject in the Treatment of Anemia Patients in the Greek Hospital Setting: a Cost Minimization Analysis [PDF]

open access: yes, 1880
Von ...
Fragoulakis, V.   +4 more
core   +1 more source

Model‐Informed Drug Development for Daprodustat Supports the Design of Individualized Dosing Regimens in Chronic Kidney Disease Patients With Anemia

open access: yesClinical Pharmacology &Therapeutics, Volume 119, Issue 2, Page 322-335, February 2026.
Model‐informed drug development (MIDD) played a crucial role in the successful development and regulatory approval of daprodustat, a novel oral hypoxia‐inducible factor prolyl hydroxylase (HIF‐PHI) inhibitor aimed at treating anemia in chronic kidney disease patients.
Kelly M. Mahar   +6 more
wiley   +1 more source

USING OF LONG ACTION ERYTHROPOES STIMULATED AGENTS FOR TREATMENT OF ANEMIA IN PATIENTS WITH CHRONIC KIDNEY DISEASES V D ST

open access: yesУкраїнський Журнал Нефрології та Діалізу, 2014
 the article describes approaches to cost optimization of anemia treatment in CKD–VDst. patients by comparison of costs in phase correction and support treatment with long action ESA in patients on HD and HDF. Aims.
M. Kolesnyk   +4 more
doaj   +1 more source

Phase II study of two dose schedules of C.E.R.A. (Continuous Erythropoietin Receptor Activator) in anemic patients with advanced non-small cell lung cancer (NSCLC) receiving chemotherapy [PDF]

open access: yes, 2007
Background C.E.R.A. (Continuous Erythropoietin Receptor Activator) is an innovative agent with unique erythropoietin receptor activity and prolonged half-life. This study evaluated C.E.R.A.
Vera Hirsh   +53 more
core   +2 more sources

Six‐Year Trends in Real‐World Data Use for Post‐Marketing Surveillance of New Medical Products in Japan

open access: yesClinical and Translational Science, Volume 19, Issue 2, February 2026.
ABSTRACT The Ministerial Ordinance on Good Post‐Marketing Study Practice for Drugs was amended by the Ministry of Health, Labour and Welfare (MHLW) in 2018 to clearly define post‐marketing database studies (DBS) as a measure of pharmacovigilance activities for approved medical products in Japan.
Suguru Okami   +2 more
wiley   +1 more source

Association Discovery Approach in Healthcare Big Data to Identify Drug Safety and Drug Repurposing Signals

open access: yesClinical Pharmacology &Therapeutics, Volume 119, Issue 1, Page 228-240, January 2026.
Data science approaches have been increasingly implemented in healthcare big data to evaluate the safety and effectiveness of drugs. Association discovery is a data mining approach that finds potentially associated elements in high‐dimensional data. We present a novel implementation of the association discovery approach in longitudinal healthcare data ...
George S. Q. Tan   +6 more
wiley   +1 more source

The effectiveness and cost-effectiveness of erythropoiesis-stimulating agents (epoetin and darbepoetin) for treating cancer-treatment induced anaemia (including review of TA142): a systematic review and economic model [PDF]

open access: yes, 2016
Background: Anaemia is a common side-effect of cancer treatments and can lead to a reduction in quality of life. Erythropoiesis-stimulating agents (ESAs) are licensed for use in conjunction with red blood cell transfusions (RBCTs) to improve cancer ...
Briscoe, Simon   +12 more
core  

CERA Detection and Stability in Blood Versus Urine

open access: yesDrug Testing and Analysis, Volume 18, Issue 1, Page 16-23, January 2026.
This study presents comparative data on CERA detection in serum and urine samples, highlighting adverse analytical findings (AAFs) in serum that were undetected in corresponding urine samples. This shift would significantly improve the efficiency and sensitivity of CERA detection in doping control, ensuring more effective doping control programs ...
Olivier Salamin   +4 more
wiley   +1 more source

Quantification of polysorbate 80 in biopharmaceutical formulations implementing an optimized colorimetric approach

open access: yesТонкие химические технологии, 2020
Objectives. We hereby describe an improvement of a previously developed quantification technique for polysorbate 80 in biopharmaceutical formulations (darbepoetin alfa and eculizumab) and report the validation of the new approach.Methods. Polysorbate was
A. S. Seregin   +4 more
doaj   +1 more source

Home - About - Disclaimer - Privacy